Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Oriol

Showing results (11-20 of 250) with videos related to

Pageof 25
Sort By:
Education for Health (Abingdon, England)|December 7, 2007
Towards unity for health in the Barceloneta: an innovative experience in community-based primary health careAndreu Segura, Frederick A Miller, Goncal Foz, et al.
The Oncologist|December 2, 2017
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect ComparisonSuzy Van Sanden, Tetsuro Ito, Joris Diels, et al.
Haematologica|July 6, 2005
Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 studyAlbert Oriol, Josep-Maria Ribera, Salut Brunet, et al.
Magma (New York, N.Y.)|April 6, 2007
In vivo quantification of response to treatment in patients with multiple myeloma by 1H magnetic resonance spectroscopy of bone marrowAlbert Oriol, Daniel Valverde, Jaume Capellades, et al.
Hematology (Amsterdam, Netherlands)|December 16, 2014
Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective studyAlbert Oriol, Pilar Giraldo, Ioannis Kotsianidis, et al.
Haematologica|June 1, 2005
The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapyJosé-Tomás Navarro, Natàlia Lloveras, Josep-Maria Ribera, et al.
Medicina Clinica|November 17, 2007
[Neutropenic enterocolitis in adult patients with acute leukemia or stem cell transplant recipients: study of 7 cases]Montserrat Batlle, Ferran Vall-Llovera, Jordi Bechini, et al.
Medicina Clinica|January 27, 2006
[Neurologic complications following hematopoietic stem cell transplantation. Study of 14 patients]Montserrat Batlle, Albert Oriol, Josep-Maria Ribera, et al.
Leukemia & Lymphoma|October 24, 2019
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trialsKatja Weisel, Istvan Majer, Lucy DeCosta, et al.
European Journal of Haematology|February 17, 2017
Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myelomaSusanna Gassiot, Cristina Motlló, Inuska Llombart, et al.
Pageof 25

Showing results (11-20 of 250) with videos related to

Sort By:
Pageof 25
Education for Health (Abingdon, England)|December 7, 2007
Towards unity for health in the Barceloneta: an innovative experience in community-based primary health careAndreu Segura, Frederick A Miller, Goncal Foz, et al.
The Oncologist|December 2, 2017
Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect ComparisonSuzy Van Sanden, Tetsuro Ito, Joris Diels, et al.
Haematologica|July 6, 2005
Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 studyAlbert Oriol, Josep-Maria Ribera, Salut Brunet, et al.
Magma (New York, N.Y.)|April 6, 2007
In vivo quantification of response to treatment in patients with multiple myeloma by 1H magnetic resonance spectroscopy of bone marrowAlbert Oriol, Daniel Valverde, Jaume Capellades, et al.
Hematology (Amsterdam, Netherlands)|December 16, 2014
Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective studyAlbert Oriol, Pilar Giraldo, Ioannis Kotsianidis, et al.
Haematologica|June 1, 2005
The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapyJosé-Tomás Navarro, Natàlia Lloveras, Josep-Maria Ribera, et al.
Medicina Clinica|November 17, 2007
[Neutropenic enterocolitis in adult patients with acute leukemia or stem cell transplant recipients: study of 7 cases]Montserrat Batlle, Ferran Vall-Llovera, Jordi Bechini, et al.
Medicina Clinica|January 27, 2006
[Neurologic complications following hematopoietic stem cell transplantation. Study of 14 patients]Montserrat Batlle, Albert Oriol, Josep-Maria Ribera, et al.
Leukemia & Lymphoma|October 24, 2019
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trialsKatja Weisel, Istvan Majer, Lucy DeCosta, et al.
European Journal of Haematology|February 17, 2017
Impact of induction treatment before autologous stem cell transplantation on long-term outcome in patients with newly diagnosed multiple myelomaSusanna Gassiot, Cristina Motlló, Inuska Llombart, et al.
Pageof 25